Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Autor: Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., Palma, G., Luciano, A., Bruzzese, F., Marino, F. Zito, Montella, M., Franco, R., Berretta, M., Gabrielli, D., Gallucci, G., Maurea, N.

Publikováno v: Frontiers in Cardiovascular Medicine; 2024, p1-18, 19p

Randomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.

Autor: Budillon A; Scientific Directorate, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy. a.budillon@istitutotumori.na.it., Leone A; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Passaro E; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Silvestro L; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Foschini F; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Iannelli F; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Roca MS; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Macchini M; Department of Medical Oncology, University 'Vita-Salute San Raffaele', IRCCS- Ospedale San Raffaele, Milan, Italy., Bruzzese F; Animal Facility Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Garcia Bermejo ML; Biomarkers and Therapeutic Targets Group, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Rodriguez Garrote M; Biomarkers and Personalized Approach to Cancer Group (BIOPAC), Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain., Tortora G; Medical Oncology, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.; Medical Oncology, Department of Translational Medicine, Catholic University of the Sacred Heart, Rome, Italy., Milella M; Section of Innovation Biomedicines-Oncology Area, Department of Engineering for Innovation Medicine (DIMI), University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy., Reni M; Department of Medical Oncology, University 'Vita-Salute San Raffaele', IRCCS- Ospedale San Raffaele, Milan, Italy., Fuchs C; EURORDIS - Rare Disease Europe, Paris, France., Hewitt E; Beacon: for rare diseases, Cambridge, UK., Kubiak C; ECRIN - European Clinical Research Infrastructure Network-European Research Infrastructure Consortium, Paris, France., Di Gennaro E; Experimental Pharmacology Unit-Laboratory of Naples and Mercogliano (AV), Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy., Giannarelli D; Facility of Epidemiology and Biostatistics, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Avallone A; Experimental Clinical Abdominal Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori 'Fondazione G. Pascale' - IRCCS, Naples, Italy. a.avallone@istitutotumori.na.it.

Publikováno v: BMC cancer [BMC Cancer] 2024 Sep 19; Vol. 24 (1), pp. 1167. Date of Electronic Publication: 2024 Sep 19.

Identification and characterization of a new potent inhibitor targeting CtBP1/BARS in melanoma cells.

Autor: Filograna A; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., De Tito S; Molecular Cell Biology of Autophagy, The Francis Crick Institute, London, UK. The Study Has Been Previously Performed at IEOS-CNR, Naples, Italy., Monte ML; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Oliva R; Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy., Bruzzese F; Animal Facility Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131, Naples, Italy., Roca MS; Experimental Pharmacology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, Naples, 80131, Italy., Zannetti A; Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), Naples, 80145, Italy., Greco A; Interdepartmental Service Center of Veterinary Radiology, University of Naples Federico II, 80137, Naples, Italy., Spano D; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Ayala I; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Liberti A; National Research Council (CNR), Piazzale Aldo Moro, 700185, Rome, Italy.; Biology and Evolution of Marine Organisms (BEOM), Stazione Zoologica Anton Dohrn, Naples, Italy., Petraccone L; Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy., Dathan N; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Catara G; Institute of Biochemistry and Cell Biology, National Research Council (CNR), 80131, Naples, Italy., Schembri L; National Research Council (CNR), Piazzale Aldo Moro, 700185, Rome, Italy.; Department of Pharmacy, University of Naples Federico II, 80131, Naples, Italy., Colanzi A; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Budillon A; Scientific Directorate, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131, Naples, Italy., Beccari AR; EXSCALATE, Dompé Farmaceutici S.P.A, Naples, Italy., Del Vecchio P; Department of Chemical Sciences, University of Naples Federico II, 80126, Naples, Italy., Luini A; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy., Corda D; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy. daniela.corda@cnr.it., Valente C; Institute of Experimental Endocrinology and Oncology 'G. Salvatore'(IEOS), National Research Council (CNR), 80131, Naples, Italy. carmen.valente@cnr.it.; Present address: Dompé Farmaceutici S.P.A, L'Aquila, Italy. carmen.valente@cnr.it.

Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2024 May 06; Vol. 43 (1), pp. 137. Date of Electronic Publication: 2024 May 06.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Autor: Bonelli, A., Canale, M.L., Bisceglia, I., Palma, G., Luciano, A., Bruzzese, F., Russo, F., Giordano, V., Maurea, C., Paccone, A., Iovine, M., Florio, F., Maurea, N., Quagliariello, V.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S1181-S1181